Business context and reporting period
The supplied filing is an unaudited Form 10-Q for GSI Group Inc. for the quarter ended June 27, 2014, with six-month comparisons to June 28, 2013. The filing describes a supplier of precision photonic and motion-control technologies serving medical and advanced industrial OEMs. Note: the request metadata names NOVANTA INC., but the filing identifies the registrant as GSI Group Inc.; verify the issuer identity before relying on this summary.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Sales | $96.9 million | $79.8 million | $176.0 million | $154.8 million |
| Gross profit / margin | $38.7 million / 39.9% | $33.2 million / 41.7% | $70.8 million / 40.2% | $63.9 million / 41.2% |
| Operating income, continuing operations | $6.5 million | $5.4 million | $10.5 million | $6.9 million |
| Income, continuing operations | $3.4 million | $1.3 million | $6.3 million | $3.0 million |
| Net income attributable to GSI Group | $0.7 million | Loss of $0.9 million | $1.7 million | $1.2 million |
| Diluted EPS, continuing operations | $0.10 | $0.03 | $0.18 | $0.08 |
Reported sales grew 21.5% in Q2 and 13.7% year to date. Management attributed most of the increase to the JADAK acquisition and favorable currency; organic growth was 0.6% and 1.0%, respectively. Q2 sales by segment were Laser Products $43.8 million, Medical Technologies $34.8 million, and Precision Motion $18.3 million. Medical Technologies’ reported growth included JADAK; legacy visualization and imaging informatics sales were affected by OEM dual sourcing and delayed product releases.
For the six months, continuing-operations operating cash flow was $19.9 million, versus $20.5 million; capital expenditures were $2.6 million. Investing cash use was $96.2 million, mainly reflecting the $93.7 million JADAK purchase. Cash fell to $45.0 million from $61.0 million at year-end. At June 27, debt totaled $134.8 million ($38.8 million term loan and $96.0 million revolver); $79.0 million remained available on the revolver. Current assets were $199.0 million and current liabilities $66.5 million. Debt covenants were met: leverage ratio 2.22 against a 3.00 maximum, and fixed-charge coverage 4.65 against a 1.50 minimum.
Material changes and unusual items
- JADAK was acquired on March 14, 2014 for $93.7 million net of cash acquired. It contributed $15.5 million of Q2 sales and $17.7 million for the six-month period. The purchase-price allocation remains preliminary; it included $44.4 million goodwill and $40.3 million identifiable intangible assets.
- Gross margin contracted year over year despite higher sales. Management cited product mix and launch/start-up costs in Laser Products and Precision Motion; Medical Technologies margin improved.
- Scientific Lasers was classified as discontinued operations. Those operations recorded losses net of tax of $2.7 million in Q2 and $4.5 million year to date, including fair-value write-downs of $1.4 million and $3.0 million, respectively. The business was sold July 15, 2014 for approximately $7.0 million cash, subject to working-capital adjustments; management expected a taxable sale loss of $0–$0.5 million in Q3.
- Interest expense increased with higher average debt and rates. The six-month foreign-exchange result shifted from a $0.8 million gain in 2013 to a loss of less than $0.1 million in 2014. Effective tax rates were 37.7% for Q2 and 32.3% year to date, above the 27% Canadian statutory rate; the filing cites jurisdictional income mix and losses without tax benefits.
Outlook, commentary and risks
No specific revenue or earnings guidance is provided. Management stated that it expected operating cash flows to meet operating and investing needs for at least the next 12 months, with revolver availability as additional liquidity. It also emphasized growth through acquisitions, product development, medical-market expansion, and operational improvements. Forward-looking results remain exposed to cyclical customer capital spending, order timing, product launches and commercialization, acquisition integration, foreign exchange and interest rates, supply interruptions, regulation, and debt/refinancing needs. Management said ordinary-course legal claims were not expected to have a material adverse effect, while noting outcomes cannot be assured. It reported effective disclosure controls and no material change in internal control during the quarter.
Most important facts to verify
- Confirm issuer identity: the supplied filing is for GSI Group Inc., although the request metadata says NOVANTA INC.
- Review JADAK integration, preliminary purchase accounting, acquired intangible amortization, and the effect of acquisition financing on earnings and leverage.
- Track organic growth separately from acquired growth, especially Medical Technologies’ legacy business and delayed releases, and monitor segment gross margins.
- Confirm final Scientific Lasers sale proceeds, working-capital adjustments, and the Q3 tax/accounting impact.
- Monitor cash generation, revolver usage and availability, covenant headroom, and the substantial long-dated JADAK capital-lease commitments.